Brief oral cryotherapy for the prevention of high-dose melphalan-induced XXXX in allogeneic hematopoietic stem cell transplant recipients.

@entity1 @entity137 @entity3136 @entity390 @entity5 @entity3118
We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced @entity3136 . The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with @entity3118 alone or with @entity3118 and additional radiation were enrolled in the study. The severity of @entity3136 was graded according to the National @entity5 Institute-Common @entity137 Criteria. @entity1 were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). @entity1 who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8%) of 17 @entity1 receiving 60-min oral cryotherapy and 2 (11.1%) of 18 @entity1 receiving 120-min oral cryotherapy developed grade 2 or 3 @entity3136 , respectively. The difference between groups was not statistically significant (P = 0.677). The incidence of unpleasant symptoms such as chills and @entity390 during oral cryotherapy decreased significantly with 60-min oral cryotherapy, as compared with that associated with 120-min oral cryotherapy (P < 0.01). These results suggest that 60-min oral cryotherapy is as effective as 120-min oral cryotherapy at preventing high-dose melphalan-induced @entity3136 , and shorter treatment might have contributed to relieve @entity1 discomfort during oral cryotherapy.
